Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

945results about How to "Shorten the progress" patented technology

Immunotherapy for clearing pathological tau conformers

ActiveUS20080050383A1Promote clearanceSlow progressionNervous disorderPeptide/protein ingredientsImmunotherapyImmunogenicity
The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.
Owner:NEW YORK UNIVERSITY

Method of treating macular degeneration with a prostaglandin derivative

A method of treating age-related macular degeneration in an eye is described, comprising contacting the eye with a therapeutic amount of a prostaglandin F2alpha derivative. The preferred prostaglandin F2alpha derivative is latanoprost, and the preferred dosage is between about 1.5 mug and about 4.5 mug per day per eye.
Owner:PAULSEN ALFRED W

Shape memory devices and methods for reshaping heart anatomy

Systems, methods and devices are provided for treating heart failure patients suffering from various levels of heart dilation. Such heart dilation is treated by reshaping the heart anatomy with the use of shape memory elements. Such reshaping changes the geometry of portions of the heart, particularly the right or left ventricles, to increase contractibility of the ventricles thereby increasing the stroke volume which in turn increases the cardiac output of the heart. The shape memory elements have an original shape and at least one memory shape. The elements are implanted within the heart tissue or attached externally and / or internally to a surface of the heart when in the original shape. The elements are then activated to transition from the original shape to one of the at least one memory shapes. Transitioning of the elements cause the associated heart tissue areas to readjust position, such as to decrease the width of the ventricles. Such repositioning is maintained over time by the elements, allowing the damaging effects of heart dilation to slow in progression or reverse.
Owner:MICARDIA CORP

Use of TNFalpha inhibitor for treatment of erosive polyarthritis

ActiveUS20070071747A1Lost timeSafe and effective meanCompounds screening/testingOrganic active ingredientsAntigen bindingPolyarthritis
The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Owner:ABBVIE BIOTECHNOLOGY LTD

Immunological targeting of pathological tau proteins

ActiveUS20100316564A1Promote clearanceSlow progressionNervous disorderMuscular disorderPeptideImmunogenicity
The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.
Owner:NEW YORK UNIVERSITY

Extra-Articular Implantable Mechanical Energy Absorbing Systems

A system and method for sharing and absorbing energy between body parts. In one particular aspect, the system facilitates absorbing energy between members forming a joint such as between articulating bones.
Owner:MOXIMED INC

Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions

ActiveUS20050105047A1Improve acuityRetarding and eliminating progressionSpectales/gogglesEye diagnosticsFocal positionOptical aberration
A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.
Owner:THE VISION CRC LTD

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.
Owner:SCHERING CORP

Methods and apparatuses for altering relative curvature of field and positions of peripheral, off-axis focal positions

ActiveUS20070115431A1Good central visionPrevent initiationSpectales/gogglesLaser surgeryPhysicsFocal position
A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.
Owner:THE VISION CRC LTD

Anti-cd20 therapeutic compositions and methods

The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
Owner:EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC +1

Means for controlling the progression of myopia

A contact lens (10) for use in controlling or retarding the progression of myopia in an eye has a central optical zone (20) approximating the normal diameter of the pupil of the eye (22) that gives clear central vision at distance for the wearer. An annular peripheral optical zone 24 that is substantially outside the diameter of the pupil is formed around the central optical zone (20) with greater refractive power than that of the central zone (22) so that oblique rays entering the eye through the peripheral optical zone (24) will be brought to focus at a focal plane that is substantially on or anterior to the peripheral region of the retina. Preferably, the rear surface (16) of the lens is shaped to conform to the cornea of the eye and the front surface (18) of the lens (10) is shaped to provide—in conjunction with the rear surface (16)—the desired optical properties of the central and peripheral optical zones. The front surface (18) is also preferably contoured to form a smooth transition (30) between the junction of the central optical zone (20) and the peripheral optical zone (24), with or without designed optical properties such as progressive power.
Owner:THE VISION CRC LTD

Growth factor for hair and skin treatment

The present invention relates to a method of treatment for slowing the progress of skin aging comprising contacting the skin with an amount effective to slow skin aging of a composition comprising one or more compounds selected from the group consisting of EGF, bFGF, IGF-1, KGF, TGF-β3, TRX, VEGF, TRX, aFGF, FGF-10, copper peptide, acetyl hexapeptide, palmitoyl pentapeptide, CPP, and UDN glycoprotein.
Owner:CAREGEN

Media file on-demand method, system and appartus

The present invention discloses a media file on-demand method, comprising: the server, upon receiving the media on-demand request from the client, provides the index information in the self-defining media file to the client; the server, upon receiving the playing progress request from said client, according to the requested time in the playing progress request, searches for the starting offset position of the media data corresponding to the requested time in the index information; the server, according to the starting offset position of the media data, reads out the media data corresponding to the requested time in the self-defining media file, and provides the media data to the client. The present invention further discloses a media file on-demand system and apparatus, wherein the index information derived by analyzing the original media file divides the original media file into individual segments according to time, thus the user, upon watching the program and dragging on the progress bar, is enabled to request the data according to the time so as to quickly acquire the media data at the time corresponding to the drag-and-drop position, so the experience of use by the user is enhanced.
Owner:TENCENT TECH (SHENZHEN) CO LTD

Distributed symmetric multiprocessing computing architecture

Example embodiments of the present invention includes systems and methods for implementing a scalable symmetric multiprocessing (shared memory) computer architecture using a network of homogeneous multi-core servers. The level of processor and memory performance achieved is suitable for running applications that currently require cache coherent shared memory mainframes and supercomputers. The architecture combines new operating system extensions with a high-speed network that supports remote direct memory access to achieve an effective global distributed shared memory. A distributed thread model allows a process running in a head node to fork threads in other (worker) nodes that run in the same global address space. Thread synchronization is supported by a distributed mutex implementation. A transactional memory model allows a multi-threaded program to maintain global memory page consistency across the distributed architecture. A distributed file access implementation supports non-contentious file I / O for threads. These and other functions provide a symmetric multiprocessing programming model consistent with standards such as Portable Operating System Interface for Unix (POSIX).
Owner:ANDERSON RICHARD S

Method of delaying the onset of clinically definite multiple sclerosis

A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.
Owner:YEDA RES & DEV CO LTD

Continuous Cell Programming Devices

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1

Substituted-pent-4-ynoic acids

InactiveUS6037367AImprove the level ofSuppressing inappropriate activationBiocideOrganic chemistryMethyl groupCarbon atom
PCT No. PCT / US96 / 11613 Sec. 371 Date Sep. 14, 1998 Sec. 102(e) Date Sep. 14, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97 / 03945 PCT Pub. Date Feb. 6, 1997Compounds of formula (I) wherein: R1 is -(CR4R5)nC(O)O(CR4R5)mR6, -(CR4R5)nC(O)NR4(CR4R5)mR6, (CR4R5)nO(CR4R5)mR6, or -(CR4R5)rR6: W is alkynyl or 2 carbon atoms; R3 is H or R7; Z is C(O)R13, (CH2)0-1C(O)OR13, (CH2)0-1C(O)NR10R13, (CH2)0-1C(R8R8)OR8, -NHC(O)R7, (CH2)0-1NR10R13, NH[C(O)C(O)OR8], CH2NH[C(O)CNR10R13], CH2S(O)qR7, CH[S(O)qR7]2, dithiolane, (tetrazol-5-yl), thiazol-2-yl, [1,2,4]thiadiazol-5-yl, [1,3,4]oxadiazol-2-yl, imidazol-2-yl, oxazol-2-yl, or (3- or 5-oxadiazolyl[1,2,4]; R7 is -(CR4R5)qR11 or C1-6 alkyl wherein the R11 or C1-6 alkyl group is unsubstituted or substituted one or more times by methyl or ethyl unsubstituted or substituted by 1-3 fluorines, -NR8R10, -CO2R8, -O(CH2qR8, -NR8C(O)R8 or R12; or the pharmaceutically acceptable salts thereof.
Owner:SMITHKLINE BECKMAN CORP

Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same

InactiveUS20070167386A1Inhibit functional expressionPreventing cardiac failureOrganic active ingredientsPeptide/protein ingredientsManagement of heart failureLeft Ventricle Remodeling
The present invention provides a drug for at least one of prevention and treatment of cardiac failure capable of suppressing cardiac depression and the onset of cardiac failure in ventricular remodeling, and a method for screening the drug. The drug for at least one of prevention and treatment of cardiac failure of the present invention contains a compound that inhibits a functional expression of ASK1 protein in a cardiomyocyte as an active ingredient, and a method for screening a drug for at least one of prevention and treatment of cardiac failure of the present invention includes selecting a medicinal component for at least one of prevention and treatment of cardiac failure from a drug candidate compound by using inhibition of a functional expression of ASK1 protein as an indication. As shown in FIG. 1, if ASK1 protein is removed, for example, the ventricle dilation can be attenuated in ventricular remodeling after myocardial infarction, pressure loading, or the like, which makes it possible to prevent and treat cardiac failure.
Owner:OSAKA INDAL PROMOTION ORG

Ophthalmic lens with an optically non-coaxial zone for myopia control

ActiveUS20190227342A1Slowing and retarding and preventing myopia progressionPrevent and retard progressionSpectales/gogglesEye treatmentOphthalmologyEye lens
The present disclosure relates to ophthalmic devices such as ophthalmic lenses. An ophthalmic device may comprise an ophthalmic lens for at least one of slowing, retarding or preventing myopia progression. The ophthalmic lens may comprise a center zone with a negative power for myopic vision correction; and at least one treatment zone surrounding the center zone, the at least one treatment zone having a power profile comprising an ADD power, the at least one treatment zone having a surface shape comprising a portion of a generally toroidal shape, wherein the at least one treatment zone is arranged as to form a continuous surface with the center zone.
Owner:JOHNSON & JOHNSON VISION CARE INC

Compositions and methods for modulating NH2-terminal Jun Kinase activity

Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.
Owner:HARVARD UNIV

Osteoarthritis treatment and device

A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and / or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.
Owner:ZIMMER KNEE CREATIONS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products